ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1518

Certolizumab Pegol Effectiveness and Retention Rate in Psoriatic Arthritis. Real Life Data

Arantxa Conesa1, Manuel Fernández2, Rosa Expósito3, Jose Campos4, Jose Ramon Lamua5, Maria del Pilar Navarro6, Paula Rubio-Muñoz7, Pilar Ahijado-Guzman8 and Carlos M Gonzalez9, 1Hospital Clínico Universitario de Valencia, Valencia, Spain, 2Hospital Universitario de Guadalajara, Guadalajara, Spain, 3Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, 4Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, 5Hospital del Henares, Madrid, Spain, 6Hospital de Fuenlabrada, Fuenlabrada, Spain, 7Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 8Rheumatology Unit. Fuenlabrada’s Hospital, Madrid, Madrid, Spain, 9Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: certolizumab pegol, Clinical Response, psoriatic arthritis and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Session Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: To evaluate the effectiveness and safety of Certolizumab Pegol (CZP) in a real word setting in Psoriatic Arthritis (PsA) patients.

Methods: Multicentric cohort of PsA patients treated with CZP according to routine clinical practice. Study approved by local Ethics Committee. Maximum time of observation is 12 months. Effectiveness variables: SJC, TJC, PtGA, PhGA and DAS28-CRP. Safety variables: discontinuation rate.

Results: 262 patients with PsA were included: 43.5% male, mean (SD) age 49.9 (±11.9) years, median disease duration 5.0 (0, 40.2) years, 14.9% of patients were HLAB27 positive, BMI (kg/m2) 26.9 (±4.7) and never smokers 70.3%.  Regarding extra-articular manifestations ever: Psoriasis (90%; PASI≥10 4.9%), enthesitis (44.4%), dactilytis (41.9%), nail disease (32%), inflammatory bowel diseases (4.9%). 37.3% of the PsA patients had erosions and a 3% arthritis mutillans (N=8). 48.9% patients received 1 prior csDMARDs and 52.1% at least 2 csDMARDs. Prior bDMARD received (28.4% none; 38.1% 1, 33.5% ≥2). 29.6% of PsA patients received CZP in monotherapy. Mean duration on treatment with CZP 10 m (78.2%).

Statistically significant differences in SJC, TJC and DAS28[CRP] were observed at the last visit comparing with baseline (Table 1). In the last observation, 47.1% of the patients had a DAS28 response (reduction of ≥1.2 from baseline). The percentage of patients with enthesitis at baseline (25.4%) was reduced to 9.5% at the end of the observation; 73.2% of the patients had a total resolution of the enthesitis (MASES=0). The percentage of patients with dactilytis at baseline (29.1%) decreased to 8.6% in the last observation; 82.5% of these patients had a total resolution of the dactilytis.

Table 1. Evolution of clinical variables of activity

 

Baseline

Last observation

DAS28-crp; mean±SD

4.6±0.9  (N=210)

3.8±1.0  (N=132)*

TJC evolution; mean±SD

7.2±5.1  (N=228)

4.0±4.0  (N=188)*

SJC evolution; mean±SD

5.0±3.7  (N=212)

2.8±2.8  (N=137)*

*p<0,001, Wilcoxon’s test

The drug survival of CZP is 78.2% (Figure1), and similar retention rates were observed independently if CZP were used as monotherapy (79.2%) or in combination with DMARDs (78.9%).

Figure 1.

262 patients were included in the safety analysis, 21.8% withdrawn treatment: 12.6% due to lack of efficacy, 5.3% due to intolerance and 3.8% other reasons.

Conclusion:  Real life experience from this nationwide study, demonstrated the effectiveness and safety of CZP in PsA patients (bionaïve only: 28.4%), with a significant reduction of DAS28, enthesitis and dactilytis. CZP survival seems to be similar regardless of csDMARDs concomitant use.  

This publication has been possible thanks to a grant of UCB Pharma to the technical companies which have been managing the data collection and the statistical analyses. The results are independent of UCB Pharma


Disclosure: A. Conesa, None; M. Fernández, None; R. Expósito, None; J. Campos, None; J. R. Lamua, None; M. D. P. Navarro, None; P. Rubio-Muñoz, None; P. Ahijado-Guzman, None; C. M. Gonzalez, MSD, Celgene, Novartis, Abbvie, Janssen, 5,MSD, Celgene, Novartis, Janssen, UCB Pharma, 8.

To cite this abstract in AMA style:

Conesa A, Fernández M, Expósito R, Campos J, Lamua JR, Navarro MDP, Rubio-Muñoz P, Ahijado-Guzman P, Gonzalez CM. Certolizumab Pegol Effectiveness and Retention Rate in Psoriatic Arthritis. Real Life Data [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/certolizumab-pegol-effectiveness-and-retention-rate-in-psoriatic-arthritis-real-life-data/. Accessed July 2, 2022.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/certolizumab-pegol-effectiveness-and-retention-rate-in-psoriatic-arthritis-real-life-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies